Nasdaq parade marches on as ex-Genmab crew at Y-mAbs reaps $96M
The story that Y-mAbs told for the first time in its IPO filing has earned the cancer biotech an upsized $92 million raise to power …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.